Published in Women's Health Weekly, April 29th, 2004
Professor Klaus Edvardsen, MD, PhD, evaluated the synergistic effects of OXi4503 with standard-of-care chemotherapy drugs Carboplatin and Paclitaxel in the MDA-MB-231 human breast adenocarcinoma and the ES-2 ovarian carcinoma models grown in mice.
"At doses ranging from 10 to 50 mg/kg, OXi4503 significantly enhanced the anti-tumor effects of the chemotherapeutic agents," said Dai Chaplin, PhD, OXiGENE's chief scientific officer and head of research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.